Patent NZ-571793-A (NZ)
Title: 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists
Inventor: STEFANY DAVID
IPC: C07D403/04
Filed: 2007-04-12
Abstract: Disclosed are the compounds 1-{ 6-[2-(2,4-Dicbloro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl} -pyrrolidine-3-carboxylic acid, 2-(1-{ 2-Methoxy-6-[2-(4-trifluorometboxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidin-3-yl)-2methyl- propionic acid, 2-[3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -5-(l-hydroxy-1-methylethyl)-phenyl]-propan-2-ol, [6-(3-Amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yl]-[2-(2,4-dichloro-phenyI)-ethyl]-amine, [6-(4-amino-piperidin-l-yl)-2-methoxy-pyrimidin-4-yI]-[2-(2,4-dichloro-phenyl)-ethyl]-amine, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-4-yl)-acetamide, S-{ 6-[2-(2,4-0ichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid, 2-Methyl-propane-2-sulfonic acid [2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyI)-2-methyl-propionyl]-amide, 10 N,N-dimethylamide-2-sulfonic acid [2-(3- { 6-[2-(2,4-dich1oro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -phenyl)-2-methyl-propionyl]-amide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-2-methyl-1-thiomorpholin-4-yl-propan-1-one, 2-(3-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)isobutyramide, 2-(3-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -phenyl)-N,N dimethylisobutyramide, (1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid, 1-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carboxylic acid, N-(1-{ 2-Methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} -piperidine-3-carbonyl)-methanesulfonamide,s-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -1-methyl-2,3-dihydro-IH-indole-2-carboxylic acid ethyl ester, (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidin-3-yl)-acetic acid ethyl ester, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl)methanesulfonamide Ethanesulfonic acid (1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} piperidine-3-carbonyl)-amide, 2-Methyl-propane-2-sulfonic acid (1-{ 6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-earbonyl)-amide, N-(1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carbonyl), trifluoro-methanesulfonamide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid(IH-tetrazol-5-yl)-amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrlmidin-4-yl} -piperidine-3-carboxylic acid amide, 1-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -piperidine-3-carboxylic acid dimethylamide, N,N-Dimethylamide-2-sulfonic acid 1-{ 6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxypyrimidin-4-yl} -piperidine-3-carboxamide, 5-{ 2-Methoxy-6-[2-(4-tritluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl} thiophene-2-carboxylic acid, or 5-{ 6-[2-(2,4-Dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl} -2,3-dihydrobenzofuran-2-carboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Also Use of the compound or a pharmaceutically acceptable salt, hydrate or solvate thereof according in the manufacture of a medicament for treating an allergic disease, systemic mastocytosis. a disorder accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, a disease accompanied by itch, a disease which is generated secondarily as a result of behaviour accompanied by itch, inflammation.,chronic obsttuctive pulmonary diseases, ischemic reperfusion injury cerebrovascular accident, chronic rheumatoid arthritism, pleurisy or ulcerative colitis.